A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Inclusion Criteria

• •Patients with CML in blast crisis, CML in accelerated phase defined as never in blast crisis phase, or CML in chronic phase defined as never been in blast crisis phase or accelerated phase who have: \*developed progressive disease during therapy with at least 600 mg of imatinib per day, -OR- \*patients with CML on imatinib therapy, at any dose, developing progressive disease and the presence of a genetic mutation likely to result in imatinib resistance -OR- \*have developed an intolerance to imatinib
• •Relapsed or refractory Ph+ ALL
• •Hypereosinophilic syndrome/chronic eosinophilic leukemia.
• •Systemic mastocytosis who have a clinical indication for treatment.
• •Prior imatinib therapy for patients with Ph+ ALL, HES/CEL and SM is permitted but is not required
• •CML patients who have been treated with an investigational tyrosine kinase inhibitor who otherwise meet the definition of imatinib-resistance or intolerance are eligible
• •Written informed consent prior to any study procedures being performed